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ABSTRACT
Objective To present results of the Kyoto Global
Consensus Meeting, which was convened to develop
global consensus on (1) classiﬁcation of chronic gastritis
and duodenitis, (2) clinical distinction of dyspepsia
caused by Helicobacter pylori from functional dyspepsia,
(3) appropriate diagnostic assessment of gastritis and (4)
when, whom and how to treat H. pylori gastritis.
Design Twenty-three clinical questions addressing the
above-mentioned four domains were drafted for which
expert panels were asked to formulate relevant
statements. A Delphi method using an anonymous
electronic system was adopted to develop the consensus,
the level of which was predeﬁned as ≥80%. Final
modiﬁcations of clinical questions and consensus were
achieved at the face-to-face meeting in Kyoto.
Results All 24 statements for 22 clinical questions after
extensive modiﬁcations and omission of one clinical
question were achieved with a consensus level of >80%.
To better organise classiﬁcation of gastritis and
duodenitis based on aetiology, a new classiﬁcation of
gastritis and duodenitis is recommended for the 11th
international classiﬁcation. A new category of H. pylori-
associated dyspepsia together with a diagnostic
algorithm was proposed. The adoption of grading
systems for gastric cancer risk stratiﬁcation, and modern
image-enhancing endoscopy for the diagnosis of
gastritis, were recommended. Treatment to eradicate
H. pylori infection before preneoplastic changes develop,
if feasible, was recommended to minimise the risk of
more serious complications of the infection.
Conclusions A global consensus for gastritis was
developed for the ﬁrst time, which will be the basis for
an international classiﬁcation system and for further
research on the subject.
INTRODUCTION
For decades endoscopic ‘gastritis,’ gastric erosions
and even histological ﬁndings of gastric inﬂamma-
tion have failed to attract much attention from clini-
cians as the majority of patients with these ﬁndings
remain asymptomatic. Although gastritis is often
used to describe dyspeptic symptoms, the presence
of such symptoms correlates poorly with histological
or endoscopic gastritis. Although the term ‘gastritis’
is still used as a concept to explain dyspeptic symp-
toms, gastritis as a term refers to gastric inﬂamma-
tion, often accompanying structural mucosal
changes.1 This gastric inﬂammation (gastritis) has
long been associated with peptic ulcer, gastric cancer
and pernicious anaemia, but the cause or causes of
gastritis remain poorly understood. The discovery
that Helicobacter pylori (H. pylori) was a cause of
gastritis2 focused attention on the aetiology, natural
history and prognosis of gastritis.
Worldwide the most common cause of chronic
gastritis is infection with H. pylori. H. pylori causes
progressive damage to the gastric mucosa and is
now accepted as playing a causative role in a
number of important diseases, including duodenal
ulcer disease, gastric ulcer disease, gastric adenocar-
cinoma and gastric mucosa-associated lymphoid
tissue (MALT) lymphoma.3–5 Indeed, H. pylori–
induced gastritis is considered as the most import-
ant risk factor for peptic ulcer and its complications
as well as for gastric cancer.5
The current International Statistical Classiﬁcation
of Diseases and Related Health Problems (ICD-10),
issued in 1989 by the International Conference for
the Tenth Revision of the ICD was endorsed by
WHO at the 43rd general assembly in 1990 and
has been used for disease statistics since 1994
among member countries of WHO. In the ICD-10,
all the digestive diseases are classiﬁed under K code
with different two-digit numbers.6 However,
H. pylori was not integrated into gastritis classiﬁca-
tion in the gastritis section (K29) of ICD-10, even
though H. pylori gastritis is the predominant type
of gastritis and clinically by far the most relevant
because of its predisposing role of severe gastro-
duodenal complications.3–5 Moreover, the current
ICD-10 classiﬁcation of gastritis is not organised
according to aetiology but is merely a mixture of
phenotype and aetiology and also includes duoden-
itis (box 1). Therefore, a revision of the gastritis
and duodenitis classiﬁcation based on all the pos-
sible aetiologies was proposed after the working
group meeting for the ICD-11 revision held
in Tokyo in 2010 and submitted as the ICD11
β foundation component. However, in the ICD11
β foundation classiﬁcation (box 2), the original
plan was changed. In an attempt to gather broader
opinions on the rationale of the new classiﬁcation
system originally proposed to ICD-11, we devoted
one section to this important issue at this meeting.
As stated above, if H. pylori gastritis is categorised
as an infectious disease, the inclusion of H. pylori
gastritis-associated dyspeptic symptoms as a ‘func-
tional disease’ entity poses a special challenge,7 8
despite it being implicated in the pathogenesis of
functional dyspepsia (FD) symptoms.9 Despite the
deﬁnition given by Rome III,9 a conceptual ambigu-
ity on how to deal with H. pylori gastritis-associated
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dyspeptic symptoms in the context of the clinical assessment of
FD still remains.5 10–12 Accordingly, guidelines and meta-analyses
that included dyspepsia associated with H. pylori under the
umbrella of ‘functional dyspepsia’5 10–12 would require reconsid-
eration in accordance with advances made in the area of
H. pylori gastritis.
Third, there has been signiﬁcant technical progress in diagnos-
tic tools for GI diseases. Advanced endoscopy with image-
enhanced modalities and magniﬁcation allows diagnosis of gastri-
tis with a high degree of accuracy, even before histological con-
ﬁrmation.13–15 Furthermore, non-invasive diagnostic tests such as
the [13C]-urea breath test, faecal antigen test and serological para-
meters serve as surrogate markers of H. pylori gastritis and indi-
cators of gastritis severity.5 Classiﬁcation systems for grading
gastritis such as the Operative Link for Gastritis Assessment
(OLGA) and Operative Link for Gastric Intestinal Metaplasia
Assessment (OLGIM) have also been proposed,16–18 in addition
to the internationally accepted Sydney System,19 20 and their
utility needs to be evaluated and agreed upon.
In 2013, the Japanese government insurance policy approved
eradication therapy for H. pylori-positive gastritis after endo-
scopic examination, to exclude more serious diseases such as
ulcer and cancer, in line with the Japanese guidelines for
H. pylori management.11 However, no global consensus has
been published on when to recommend eradication therapy for
H. pylori gastritis and how to follow up after eradication.
Since the global awareness of gastritis is still confounded by a
number of controversial issues as described above, a meeting
was set up in Kyoto to achieve global consensus on H. pylori
gastritis; to attempt conceptual changes in gastritis classiﬁcation
in general; to agree diagnosis and management strategies with
special reference to FD and cancer prevention.
METHOD
Consensus development process
Four major topics were chosen by core members of the orga-
nising committee (KS, NU and PM). Drafts of clinical ques-
tions (CQs) about each topic were prepared by the ad hoc
committee of the Japanese Society of Gastroenterology
( JSGE) and were further revised by core members (KS, PM
and EME-O). Altogether, 23 CQs were selected for the ﬁrst
round of voting.
Faculty members were selected from members of the JSGE,
European Helicobacter Study Group, Asian Paciﬁc Association
of Gastroenterology, Healthy Stomach Initiative and the
working group members of gastroenterology for ICD-11. These
members were assigned to one of the four subgroups by core
members (KS, NU and PM) based on their expertise and two
members from each subgroup were invited to serve as modera-
tors. The faculty members of each group were assigned one or
two CQs for which they were asked to prepare statements and
supporting evidence. These statements were edited by modera-
tors and core members and uploaded to the electronic voting
system developed by JSGE.
The Delphi method was used for consensus development, and
voting by each faculty member was done anonymously through
the electronic system. Each faculty member was asked to indi-
cate one of the following levels of agreement: strongly agree,
agree with minor reservation, agree with major reservation, dis-
agree with minor reservation, disagree with major reservation
and strongly disagree. If the member’s vote was other than
strongly agree or agree with minor reservation, they were asked
to give the reasons for reservation or disagreement.
Consensus level was predeﬁned as ≥80% of the sum of the
votes of strongly agree plus agree with minor reservation.
After the ﬁrst round of voting, moderators in each subgroup
initiated further discussion about the statements which had
failed to reach consensus. After this discussion, the revised
statements were uploaded to the electronic voting system for
a second round of voting. This process resulted in several
CQs being modiﬁed for improved understanding and to
better ﬁt the statements. At the second round of voting,
faculty members were asked to provide recommendation as to
the grade of evidence and the levels of supporting evidence
for the statements. Recommendation grade and evidence level
were based on the GRADE system21 22 (see online supplemen-
tary table S1 and S2). Electronic reminders were automatically
sent to all faculty members twice (3 days and 1 day before the
closing dates). Voting rates of 100% were achieved in the two
voting sessions.
The second round of voting was followed by a face-to-face
meeting in Kyoto on 31 January to 1 February 2014. On the
ﬁrst day, preliminary plenary voting was conducted since
faculty members had hitherto been blinded to the voting
results in other sections. This process identiﬁed several state-
ments which failed to achieve consensus of ≥80%. Each
group then met to resolve disagreements and better reﬂect
opinions from all group members. On the second day, the
revised statements were presented at plenary discussions with
all group members. Voting for each statement was done using
a key pad system with the levels of agreements being shown
on the screen in real time. Statements that failed to reach con-
sensus were discussed, revised if considered necessary and
voted on again. Finalised statements were summarised by
moderators assigned to each group.
The ﬁve colleagues who could not attend the face-to-face
meeting or missed the ﬁnal voting were invited later to give
Box 1 Current International Statistical Classiﬁcation of
Diseases and Related Health Problems (ICD-10)
classiﬁcation of gastritis (K29 code) http://apps.who.int/
classiﬁcations/icd10/browse/2015/en#/K29
K29 Gastritis and duodenitis
Excl: eosinophilic gastritis or gastroenteritis (K52.8)
Zollinger–Ellison syndrome (E16.4)
K29.0 Acute haemorrhagic gastritis
Incl: Acute (erosive) gastritis with haemorrhage
Excl: erosion (acute) of stomach (K25.–)
K29.1 Other acute gastritis
K29.2 Alcoholic gastritis
K29.3 Chronic superﬁcial gastritis
K29.4 Chronic atrophic gastritis
Incl: Gastric atrophy
K29.5 Chronic gastritis, unspeciﬁed
Incl: Chronic gastritis
Antral
Fundal
K29.6 Other gastritis
Incl: Giant hypertrophic gastritis
Granulomatous gastritis
Ménétrier disease
K29.7 Gastritis, unspeciﬁed
K29.8 Duodenitis
K29.9 Gastroduodenitis, unspeciﬁed
Excl, exclusion criteria; Incl, inclusion criteria.
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their votes for all the ﬁnalised statements without notiﬁcation of
the plenary voting results. The impact of their votes is discussed
below.
For management of conﬂict of interest (COI), each member
was asked to present COI status according to the JSGE guide-
lines. If a relevant COI had existed, that person would have been
asked not to vote, in accordance with the recent consensus,23 but
no such case was encountered. The majority of the funding was
provided by JSGE with a hand-reach support from industries,
which were otherwise not involved in the planning, organisation
or manuscript writing and did not join in the discussions.
Box 2 Classiﬁcation of gastritis (2A) and duodenitis (2B)
in the foundation component of International Statistical
Classiﬁcation of Diseases and Related Health Problems
(ICD11 β) (as accessed at 20 January 2015) http://apps.
who.int/classiﬁcations/icd11/browse/f/en#/
Please note that this classiﬁcation is continuously updated and
hence is subject to change. This classiﬁcation is not authorised
by WHO.
2A Classiﬁcation of gastritis at the foundation layer of
ICD11 β
Helicobacter pylori-induced gastritis
Drug-induced gastritis
Autoimmune gastritis
Stress-induced gastritis
Special forms of gastritis
▸ Allergic gastritis
▸ Gastritis due to biliary reﬂux
▸ Lymphocytic gastritis
▸ Ménétrier disease
▸ Eosinophilic gastritis
Infectious gastritis
▸ Gastric phlegmone
▸ Bacterial gastritis
H. pylori-induced gastritis
Enterococcal gastritis
Mycobacterial gastritis
Tuberculous gastritis
Non-tuberculous mycobacterial gastritis
Mycobacterium avium-intracellulare gastritis
Gastritis due to other speciﬁed non-tuberculous
mycobacteria
Secondary syphilitic gastritis
▸ Viral gastritis
Cytomegaloviral gastritis
Enteroviral gastritis
▸ Fungal gastritis
Gastritis due to mucoromycosis
Gastric candidiasis
Gastric histoplasmosis
▸ Parasitic gastritis
Gastric anisakiasis
Cryptosporidium gastritis
Gastric strongyloides stercoralis
Gastritis due to other diseases classiﬁed elsewhere
▸ Gastritis due to Crohn’s disease
▸ Gastritis due to sarcoidosis
▸ Gastritis due to vasculitis
Gastritis due to external causes
▸ Alcoholic gastritis
▸ Radiation gastritis
▸ Chemical gastritis
▸ Gastritis due to other speciﬁed external causes
Gastritis of unknown aetiology with speciﬁc endoscopic or
pathological features
▸ Superﬁcial gastritis
Acute superﬁcial gastritis
Chronic superﬁcial gastritis
▸ Acute haemorrhagic gastritis
▸ Chronic atrophic gastritis
Mild to moderate gastric atrophy
Severe gastric atrophy
▸ Metaplastic gastritis
▸ Granulomatous gastritis
▸ Hypertrophic gastritis
Other gastritis
▸ Chronic gastritis, not elsewhere classiﬁed
▸ Acute gastritis, not elsewhere classiﬁed
2B Classiﬁcation of duodenitis at the foundation layer
Helicobacter pylori-induced duodenitis
Stress-induced duodenitis
Duodenitis due to external causes
▸ Alcoholic duodenitis
▸ Chemical duodenitis
▸ Radiation duodenitis
▸ Duodenitis due to other external causes
▸ Drug-induced duodenitis
Special forms of duodenitis
▸ Allergic duodenitis
▸ Eosinophilic duodenitis
▸ Lymphocytic duodenitis
Infectious duodenitis
▸ Duodenal phlegmone
▸ Bacterial duodenitis
Mycobacterial duodenitis
Non-tuberculous mycobacterial duodenitis
Tuberculous duodenitis
Duodenitis due to Whipple’s disease
▸ Fungal duodenitis
Duodenal candidiasis
▸ Parasitic duodenitis
Ancylostomiasis duodenitis
Duodenal anisakiasis
Duodenitis due to Giardia lamblia
Strongyloides duodenitis
▸ Viral duodenitis
Cytomegaloviral duodenitis
Herpetic duodenitis
Duodenitis due to other diseases, classiﬁed elsewhere
▸ Duodenitis due to coeliac disease
▸ Duodenitis due to Crohn’s disease
▸ Duodenitis due to sarcoidosis
▸ Duodenitis due to vasculitis
Duodenitis due to IgA vasculitis
▸ Duodenitis due to Whipple’s disease
Duodenitis of unknown aetiology with speciﬁc endoscopic or
pathological features
▸ Acute haemorrhagic duodenitis
▸ Granulomatous duodenitis
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Process and results
At the ﬁrst round of voting 16 CQs achieved the predeﬁned
consensus level of ≥80%. Six statements failed to reach consen-
sus and each section met to modify their assigned statements
based on the comments and opinions received. This led to some
questions being split into two or being combined, resulting in
24 CQs, including 25 statements which were subjected to the
second round of voting within their assigned group. The results
of the second round of voting were disclosed on the ﬁrst day of
the face-to-face meeting in Kyoto. At this stage, all statements
except one had achieved consensus. To facilitate further discus-
sion in the break-out sessions, preliminary plenary voting was
done to enable the respective section members to consider the
opinions of all group members.
On the second day, the ﬁnalised CQs and accompanying state-
ments were presented for plenary voting. If consensus levels
were not reached, open discussions ensued to modify the state-
ments, followed by voting. All the ﬁnalised CQs and statements
are shown in the four consensus sections. Levels of recommen-
dation and evidence are shown together with the voting results.
For CQ1 to CQ8A, 39 members voted, while 38 voted for
CQ8B to CQ14A and 37 voted for CQ14B to CQ23. During
the plenary voting, one subdivided CQ (CQ19) was recom-
bined, while another CQ (CQ21) was deleted because of redun-
dancy, resulting in 22 CQs and 24 statements. All voting during
the plenary session was done anonymously by an electronic
voting system with key pads distributed to each faculty member.
The ﬁve faculty members who missed the plenary voting session
were asked to vote later for the ﬁnalised CQs and statements
without knowledge of the plenary voting results. Their voting
results were almost identical with the plenary voting results.
They agreed on all the CQs with the only exception being
CQ11, showing 80% (one out of ﬁve) agreement. Since there
was no inconsistency between the plenary voting and voting by
the absentees, combining the two sets of results did not inﬂu-
ence the outcome. The entire consensus results are shown
below.
CONSENSUS STATEMENT
Section 1. Classiﬁcation of gastritis in relation to ICD-11
CQ1. Is the current ICD-10 classiﬁcation for gastritis
appropriate?
Statement 1
The current ICD-10 classiﬁcation for gastritis is obsolete in view
of the discovery of H. pylori.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
The ICD-10 classiﬁcation of gastritis was formulated in 1989
and is still in effect in most countries. At the time of formula-
tion, the ICD-10 classiﬁcation of gastritis and duodenitis (K29)
was rudimentary as it was based on macroscopic and histomor-
phological criteria; the only aetiological factor assigned was
alcohol6 (box 1). The histological classiﬁcation of gastritis con-
sidered mainly aspects of atrophy and autoimmunity.1
The discovery of H. pylori had not been taken into account,
possibly because even though release came after the discovery of
Campylobacter pylori (H. pylori), the role of H. pylori in disease
was still controversial. The recognition of H. pylori infection as
the primary cause of chronic gastritis proved to be a break-
through that reopened the chapter on gastritis and its role in
disease.2 24 25 At present, no classiﬁcation of gastritis would be
complete without including H. pylori as the aetiological cause.
CQ2. Is the proposed ICD-11 classiﬁcation for gastritis
appropriate?
Statement 2
The newly proposed classiﬁcation of gastritis in the ICD11 β
version is an improvement because it is based on aetiological
factors.
Grade of recommendation: strong
Evidence level: moderate
Consensus level: 100%
Comment
Although the ICD-10 has been updated regularly to accommodate
new diseases and concepts, WHO recognised the necessity of
overall systematic changes in the ICD and decided to revise the
current ICD-10 to ICD-11 in 2007. As the intermediate process
for this revision, the ICD11 β version was formulated with input
from various scientiﬁc advisory groups. This version was open to
the public so that opinions from various interest groups and a
broader range of medical specialists could be reﬂected before com-
piling the ICD-11. ICD11 β foundation component consists of the
core of the ICD-11 classiﬁcation from which mortality and mor-
bidity classiﬁcations will derive. However, it remains a draft and
can be changed from time to time before ﬁnalisation of ICD-11
(for more details, please visit http://www.who.int/classiﬁcations/
icd/revision/betaexpectations/en/).
In the ICD11 β foundation component of the gastritis
section, classiﬁcation of gastritis was principally based on aetio-
logical factors with consideration of their speciﬁc pathophysio-
logical principles (box 2). Accordingly, H. pylori gastritis is
categorised as a speciﬁc nosological entity.
The assessment of gastritis based on histopathological criteria
was completely changed after recognition of H. pylori as the
most common cause of chronic gastritis. The Sydney System
was developed as a consequence and has been integrated into
clinical practice. The Sydney classiﬁcation of gastritis combined
histological parameters of activity, chronicity, atrophy, intestinal
metaplasia, topographical distribution and aetiopathogenic
information for reporting the pathology of gastritis in endo-
scopic biopsies.19 20
As described above, classiﬁcation of gastritis in the foundation
component of ICD11 β version is principally based on causative
factors, in order to cover the three most important and best
deﬁned categories of gastritis—namely, (a) H. pylori-induced,
(b) drug-induced and (c) autoimmune gastritis. A speciﬁc diag-
nosis among these different categories of gastritis is required to
direct speciﬁc management and treatment strategies. The diag-
nosis of H. pylori-induced gastritis has major implications for
life-long healthcare. H. pylori gastritis may cause dyspeptic
symptoms26 27 and result in gastroduodenal pathologies, includ-
ing peptic ulcer disease (PUD) and gastric cancer. The recog-
nised role of H. pylori as a carcinogen makes eradication of
H. pylori infection the preferred strategy for the prevention of
gastric cancer.5 11 28 There is more to learn about aetiologies
other than H. pylori in gastritis and this is dealt with as
‘H. pylori-negative or idiopathic gastritis’.29
The proposed aetiology-based classiﬁcation for gastritis in the
foundation component of ICD11 β version was further reﬁned by
this consensus meeting (box 3). Clinical validation is needed to
further deﬁne and conﬁrm the usefulness of the new classiﬁcation.
Furthermore, duodenitis, which was in the gastritis section in
ICD-10, is now categorised in an independent section in the
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foundation component. It should be noted that the Joint
Linearisation of Mortality and Morbidity of ICD11 β version is
now publicly available (see online supplementary table S3) and
differs signiﬁcantly from the foundation component (box 2) or
aetiology-based classiﬁcation proposed in this paper (box 3).
This linearisation did not adopt the principle of aetiology-based
classiﬁcation, thus requiring further revision.
CQ3. Is it necessary to categorise gastritis according to gastric
subsite?
Statement 3
It is useful to categorise H. pylori-induced gastritis according to
gastric subsites, because the risks of gastric cancer and peptic
ulcer are affected by the patterns of gastritis.
Grade of recommendation: strong
Evidence level: high
Consensus level: 97.4%
Comment
The categorisation of H. pylori gastritis according to gastritis
subsites together with the assessment of gastritis severity allows
prediction of an individual’s risk of developing severe gastro-
duodenal complications and, in particular, gastric cancer.30–32
Depending on the gastric subsites involved, gastric function
and, in particular, gastric acid secretion may be profoundly
affected, resulting in gastric acid hypersecretion, hyposecretion
or even achlorhydria.33–35
Subsite characterisation of gastritis is also critically important
for identifying those patients who remain at high risk after
H. pylori eradication and thus are candidates for regular endo-
scopic and histological follow-up.36 Patients with severe atrophic
gastritis (with or without intestinal metaplasia) in the corpus or
with severe corpus predominant gastritis are those at highest
risk for progression to gastric cancer of the intestinal type31 37
and for diffuse-type gastric cancer. In diffuse-type gastric cancer
the prevalence of antral atrophic gastritis is almost identical to
that seen in the intestinal type but is slightly less with corpus
atrophic gastritis than with intestinal type gastric cancer.38
CQ4. Is it necessary to categorise gastritis according to
histology (severity) and/or endoscopy?
Statement 4
It is advisable to categorise gastritis according to histology,
because the risk of development of gastric cancer in H. pylori
Box 3 Aetiology-based classiﬁcation of gastritis (3A)
and duodenitis (3B). A proposal according to the
consensus at the Kyoto consensus conference
3A Proposed classiﬁcation of gastritis in the Kyoto consensus
conference
Autoimmune gastritis
Infectious gastritis
▸ Helicobacter pylori-induced gastritis
▸ Bacterial gastritis other than H. pylori
Helicobacter heilmannii gastritis
Enterococcus gastritis
Mycobacteria gastritis
Secondary syphilitic gastritis
▸ Gastric phlegmone
▸ Viral gastritis
Enteroviral gastritis
Cytomegalovirus gastritis
▸ Fungal gastritis
Gastritis due to mucormycosis
Gastric candidiasis
Gastric histoplasmosis
▸ Parasitic gastritis
Cryptosporidium gastritis
Gastric strongyloides stercorale
Gastric anisakiasis
Gastritis due to external causes
▸ Drug-induced gastritis
▸ Alcoholic gastritis
▸ Radiation gastritis
▸ Chemical gastritis
▸ Gastritis due to duodenal reﬂux
▸ Gastritis due to other speciﬁed external cause
Gastritis due to speciﬁed causes
▸ Lymphocytic gastritis
▸ Ménétrier disease
▸ Allergic gastritis
▸ Eosinophilic gastritis
Gastritis due to other diseases classiﬁed elsewhere
▸ Gastritis due to sarcoidosis
▸ Gastritis due to vasculitis
▸ Gastritis due to Crohn’s disease
3B Proposed classiﬁcation of duodenitis in the Kyoto consensus
conference
Infectious duodenitis
▸ H. pylori-induced duodenitis
▸ Bacterial duodenitis other than H. pylori
Mycobacterial duodenitis
Duodenitis due to Tropheryma whipplei (Whipple’s
disease)
▸ Duodenal phlegmone
▸ Fungal duodenitis
Duodenal candidiasis
▸ Parasitic duodenitis
Ancylostomasis (hookworm) duodenitis
Duodenal anisakiasis
Duodenitis due to Giardia lamblia
Strongyloides duodenitis
▸ Viral duodenitis
Cytomegaloviral duodenitis
Herpetic duodenitis
Duodenitis due to external causes
▸ Alcoholic duodenitis
▸ Chemical duodenitis
▸ Radiation duodenitis
▸ Duodenitis due to other external causes
▸ Drug-induced duodenitis
Duodenitis due to speciﬁed causes
▸ Allergic duodenitis
▸ Eosinophilic duodenitis
▸ Lymphocytic duodenitis
Duodenitis due to other diseases classiﬁed elsewhere
▸ Duodenitis due to Crohn’s disease
▸ Duodenitis due to sarcoidosis
▸ Duodenitis due to vasculitis
▸ Duodenitis due to Henoch–Schönlein purpura
▸ Duodenitis due to coeliac disease
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gastritis varies according to the extent and severity of inﬂamma-
tion and atrophy.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
The updated Sydney System has been globally implemented into
clinical practice and requires proper assessment of all the rele-
vant characteristics of H. pylori gastritis including atrophy
and intestinal metaplasia at different gastric subsites.19 20
Categorising gastritis is clinically relevant because the ‘pheno-
type’ of H. pylori gastritis determines the risk of progression to
gastroduodenal complications.
Severity and extent of atrophic gastritis and intestinal
metaplasia are well established as indicators of the increased risk
for developing gastric cancer.31 39 40 Similarly, severe
H. pylori-induced corpus gastritis is associated with an increased
risk for gastric cancer.31 41 New staging systems for the charac-
terisation of gastritis have been introduced to assess the gastric
cancer risk. They are used in clinical practice and are either
based on the severity of atrophy in various gastric subsites
(OLGA)16 17 or on intestinal metaplasia (OLGIM).18 Both
systems, discussed further in section 3, are reported to have a
positive impact on patient management.
CQ5. How should we classify gastric erosions in the context of
chronic gastritis?
Statement 5
Gastric erosions should be reported separately from gastritis.
The natural history and clinical signiﬁcance of gastroduodenal
erosions depend on aetiology and need further clariﬁcation.
Grade of recommendation: strong
Evidence level: low
Consensus level: 100%
Comment
Gastric erosions are deﬁned as superﬁcial mucosal breaks with a
diameter of <3 mm or <5 mm.42 This small size makes it less
likely to confound erosions with peptic ulcers which, by deﬁn-
ition, penetrate the muscularis mucosae.3
Gastric erosions can be detected in the context of H. pylori
infection but are more frequently caused by intake of mucosal
damaging drugs—in particular, aspirin and non-steroidal anti-
inﬂammatory drugs (NSAIDs).43 44
Furthermore, several different morphological forms were
noted after eradication of H. pylori as (a) ﬂat, (b) raised,
(c) haemorrhagic and (d) appearing as bleeding spots with local-
isation in the antrum in the absence of drugs,45 possibly owing
to hyperacidity after eradication therapy.46 47
From a clinical perspective, the most relevant aspect of ero-
sions is that patients taking NSAIDs and having numerous ero-
sions in the stomach are at increased risk of developing ulcers
subsequently.48
Few studies on the clinical signiﬁcance or natural history of
gastric or duodenal erosions have been reported. Thus, it is
important to conduct a prospective research in which erosions in
the stomach and duodenum are separately reported in conjunc-
tion with the category of gastritis, which is needed to better
understand the natural history of gastric erosions and their
potential to progress to ulceration and bleeding. Validated scores
for reporting erosions for research purposes should be used.49
CQ6. Is H. pylori gastritis an infectious disease irrespective of
symptom and complications?
Statement 6
H. pylori gastritis should be deﬁned as an infectious disease,
even when patients have no symptoms and irrespective of com-
plications such as peptic ulcers and gastric cancer.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
H. pylori gastritis is an infectious disease and leads to chronic active
gastritis of varying severity in virtually all infected subjects.50
There is a signiﬁcant variability in the interindividual expres-
sions of gastric mucosal structural damage and accordingly the
associated physiological perturbations also vary.30 35 H. pylori
gastritis may remain clinically unapparent or evolve into severe
complications. The rate of progression is unpredictable. The
most severe clinical expression is gastric cancer, which is often
incurable by the time of diagnosis.
Cure of H. pylori infection leads to healing of the inﬂamed
gastric mucosa, which may return to normal. H. pylori eradica-
tion may improve or resolve dyspeptic symptoms and usually
cures PUD. H. pylori gastritis is a disease which can be cured
and thus prevent severe complications. If H. pylori gastritis has
progressed to more severe forms of gastritis, including atrophic
gastritis with or without intestinal metaplasia, or severe corpus
predominant gastritis, the risk of gastric cancer is increased and
eradication of the infection at this stage needs to be integrated
with a follow-up strategy.5 11 28 31 36 40
Section 2 Dyspepsia associated with H. pylori infection
CQ7. Does H. pylori gastritis cause dyspepsia?
Statement 7
H. pylori gastritis is the cause of dyspepsia in a subset of patients.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
A large number of observations support the conclusion that
H. pylori infection may be a cause of symptoms in a proportion
of patients presenting with dyspepsia.26 27 First, acute iatrogenic
or self-administered infection with H. pylori can induce acute
dyspeptic symptoms.24 25 However, while persistent colonisation
virtually always leads to chronic gastritis,48 in the majority of
individuals severe dyspeptic symptoms are transient.24 25 51
Second, most but not all, epidemiological studies show associa-
tions between H. pylori infection and (uninvestigated) dyspeptic
symptoms.52–55 The most convincing evidence can be derived
from H. pylori eradication studies in infected patients with unin-
vestigated or FD.12 56–61 In these studies, eradication is associated
with a small but statistically signiﬁcant beneﬁt for symptom
control over no eradication; the estimated number needed to
treat is 1412 and in a more recent study the number was 8.61 At
present there are no criteria to predict whether a patient with
dyspeptic symptoms will respond to eradication therapy or not.
Therefore, the only way in clinical practice is to eradicate the
H. pylori infection and see whether symptoms resolve or
whether additional treatments will be required. The symptomatic
gain takes at least 6 months to become signiﬁcant over no eradi-
cation and this has been attributed to the time it takes for gastritis
to recover.12 59–61
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CQ8. Should we categorise H. pylori-associated dyspepsia as a
speciﬁc entity?
Statement 8A
In H. pylori-infected patients with dyspepsia, symptoms can be
attributed to H. pylori gastritis if successful eradication therapy
is followed by sustained symptom remission.
Grade of recommendation: strong
Evidence level: high
Consensus level: 97.4%
Statement 8B
H. pylori-associated dyspepsia (as in statement 8A) is a distinct
entity.
Grade of recommendation: strong
Evidence level: moderate
Consensus level: 92.1%
Comment
Based on the Rome III consensus,9 62 FD is deﬁned as “the pres-
ence of chronic dyspeptic symptoms (postprandial fullness,
early satiation, epigastric pain or burning) without evidence of
structural disease (including at upper endoscopy) that is likely to
explain the symptoms” (ﬁgure 1). This group was contrasted
with those in whom chronic dyspeptic symptoms have an identi-
ﬁed organic or metabolic cause, where elimination of that cause
or improvement of the disease leads to resolution or improve-
ment of symptoms.9
The Rome III consensus mentions a subset of patients with
H. pylori gastritis as representative of organic dyspepsia if they
respond to eradication. Patients with H. pylori gastritis in whom
symptoms persist despite eradication therapy eliminating the infec-
tion were identiﬁed as having FD.9 As mentioned above, eradica-
tion therapy studies showed that a subset of H. pylori-infected
patients with FD derive symptomatic beneﬁt from eradication,
with a delay of at least 6 months from cure of the infection.12 59–61
Based on these considerations, sustained symptom control
after successful eradication identiﬁes H. pylori as the organic
cause of the symptoms in these patients and provides the ration-
ale to consider H. pylori-associated dyspepsia as a separate clin-
ical entity. H. pylori-infected patients with chronic dyspeptic
symptoms and negative endoscopy are now treated and labelled
depending on their treatment response as outlined in ﬁgure 1.
CQ9. Is eradication of H. pylori infection ﬁrst-line treatment
for improving dyspeptic symptoms?
Statement 9
Eradication of H. pylori is ﬁrst-line treatment for
H. pylori-infected dyspeptic patients.
Grade of recommendation: strong
Evidence level: high
Consensus level: 94.7%
Comment
As is apparent from statement 8, there is a group of patients
with FD for whom H. pylori is considered the cause of their
symptoms, and this can be established if eradication is associated
with sustained symptom beneﬁt.9 59–61 This scenario is the only
one where patients with chronic dyspeptic symptoms and a
negative endoscopy can be ‘cured’, albeit with some delay after
successful eradication therapy.12 59–61 Moreover, very few effect-
ive alternative therapeutic approaches have been proved to have
substantial and sustained beneﬁt in FD.63 Finally, eradication
therapy is a short treatment, with acceptable cost–beneﬁt for
controlling dyspeptic symptoms, and with other potential bene-
ﬁts for prevention of peptic ulcer and gastric cancer.5 Based on
these considerations, eradication therapy can be proposed as
ﬁrst-line treatment for H. pylori-infected dyspeptic patients,
which is in line with a recent management algorithm by the
Rome foundation.64
CQ10. How effective is H. pylori eradication on dyspeptic
symptoms—in the short and long term—and how does it
compare with other treatments (such as proton pump inhibitors
(PPIs))?
Statement 10
In H. pylori-infected dyspeptic patients, eradication therapy for
dyspeptic symptoms is better than placebo and is the preferred
option.
Grade of recommendation: strong
Evidence level: high
Consensus level: 97.4%
Comment
Eradication therapy studies have conﬁrmed that a subset of
H. pylori-infected patients with FD is relieved of dyspeptic
symptoms by eradication therapy.12 56–61 To date, only a limited
number of studies have directly compared eradication therapy
with other treatments that are used for FD, such as PPIs or pro-
kinetic therapy.57 60 61 Hence, although the symptomatic gain
takes at least 6 months,57 60 61 eradication is the preferred treat-
ment. Future trials should compare eradication with treatment
modalities other than placebo in H pylori-infected patients with
chronic dyspeptic symptoms and a negative endoscopy.
CQ11. Should patients who remain dyspeptic after successful
H. pylori eradication be considered to have FD?
Statement 11
Figure 1 Diagnostic algorithm of Helicobacter pylori-associated
dyspepsia. Patients with dyspeptic symptoms after negative routine
laboratory and upper gastrointestinal endoscopy except for positive
H. pylori tests, should undergo eradication therapy. If sustained
symptomatic relief is obtained, their dyspeptic symptoms are considered
as H. pylori-associated dyspepsia. On the other hand, if dyspeptic
symptoms do not resolve or recur after eradication therapy, they are
judged to have functional dyspepsia. EGD, oesophagastroduodenoscopy.
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Patients who remain symptomatic after successful H. pylori
eradication should be considered to have FD.
Grade of recommendation: weak
Evidence level: moderate
Consensus level: 97.4%
Comment
As indicated in statements 8A and 8B and in agreement with the
Rome III criteria,9 62 H. pylori infected dyspeptic patients with
negative endoscopy who experience sustained symptom control
are labelled as having H. pylori-associated dyspepsia.
Conversely, when symptoms do not beneﬁt in the long term
from successful eradication, this indicates that H. pylori gastritis
did not cause the symptoms in these patients. Consequently,
they can keep the label ‘functional dyspepsia’ (ﬁgure 1).
Section 3 Diagnosis of gastritis
CQ12. Is it possible to make a diagnosis of atrophy and/or
intestinal metaplasia by endoscopy?
Statement 12
Atrophic mucosa and intestinal metaplasia can be accurately
detected by image-enhanced endoscopy, after appropriate training.
Grade of recommendation: strong
Evidence level: high
Consensus level: 84.2%
Comment
Conventional endoscopy is, in most hands, an inadequate tool
for diagnosing atrophy and intestinal metaplasia and therefore it
remains mandatory that a biopsy is carried out, allowing histo-
morphological assessment of the gastric mucosa according to the
Sydney classiﬁcation.19 20 However, image-enhanced endoscopy
has improved the accuracy and reproducibility of endoscopic
diagnosis of premalignant gastric lesions. This includes chro-
moendoscopy,65 high-resolution magniﬁcation endoscopy66 67
and image-enhanced endoscopy combined with magniﬁca-
tion15 68–72 (ﬁgure 2). These methods are now routinely available
in Japan and will be increasingly used worldwide. Adequate
evaluation of the stomach mucosa with each of these methods
requires appropriate training66 and offers the advantage of tar-
geted biopsies.
CQ13. Is the updated Sydney System appropriate for histo-
logical diagnosis of gastritis?
Statement 13
Accurate histological assessment of gastritis requires biopsy sam-
pling of both antrum and corpus.
Grade of recommendation: strong
Evidence level: high
Consensus level: 92.1%
Comment
Premalignant lesions of the stomach may be unevenly distribu-
ted. Therefore, accurate histological assessment of gastritis
requires biopsy sampling of both antrum and corpus. This may
facilitate the classiﬁcation and grading of preneoplastic gastric
lesions.73 Various studies have shown that more extensive
biopsy sampling increases the diagnostic yield for identifying
patients with premalignant lesions and provides a better over-
view of the severity and distribution of these lesions.74–76
This also has practical limitations, which led to the updated
Sydney System. This provides guidance on the methods of
sampling and the histopathological grading of individual
abnormalities—in particular, inﬂammation, gland loss and
metaplasia.20 The Sydney System recommends routine
Figure 2 Image enhanced endoscopy. (A) Narrow band imaging (NBI) of the gastric mucosa. Round homogeneous sized pits with regularly
arranged collecting venules are shown (left). This pattern (regular arrangement of collecting venules) named ‘RAC’ pattern in the corpus mucosa
highly indicates a Helicobacter pylori negative state.13 In the H. pylori-infected mucosa with inﬂammation, pit patterns are elongated, varied in sizes
and shapes with spaces between them. Collecting venules are obscured owing to inﬂammation (centre).14 When intestinal metaplasia develops, the
pit pattern is further elongated with light blue lines (light blue crest sign) decorating the pits margins (right).66 The images were provided by
Dr Kazuyoshi Yagi. (B) Blue laser imaging (BLI) of the gastric mucosa. BLI is a new modality of image enhancement.70 The BLI-bright mode can
easily obtain lower magniﬁcation images, similar to the NBI images in (A) (left). With BLI-magniﬁcation mode, further mucosal details including
periglandular capillary networks (red coloured circles surrounding the pits) are seen (centre). BLI endoscopy is useful for identifying the area of
intestinal metaplasia where greenish coloured elongated pit patterns predominate (right). The images were provided by Dr Hiroyuki Osawa, Jichi
Medical University.
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sampling of ﬁve gastric biopsy specimens: antrum greater and
lesser curvature, incisura and corpus greater and lesser curva-
ture. Specimens need to be put into separate vials and grouped
for each site or lesion. The system is widely used; the most
common modiﬁcation being to leave out the separate incisura
sample.36 It is of key importance that separate specimens are
obtained from endoscopically visible lesions. The accuracy of
image-enhanced endoscopy in trained hands further increases
the yield of targeted biopsies.66 77 78
CQ14. Are grading systems such as OLGA and OLGIM useful
for risk stratiﬁcation?
Statement 14A
Gastric cancer risk correlates with the severity and extent of
atrophic gastritis.
Grade of recommendation: strong
Evidence level: high
Consensus level: 94.7%
Statement 14B
Histological staging systems such as OLGA and OLGIM are
useful for risk stratiﬁcation.
Grade of recommendation: strong
Evidence level: low
Consensus level: 97.3%
Comment
Most gastric cancers are triggered by longstanding gastritis, pri-
marily due to H. pylori infection. This can occur via a multistep
pathway of precancerous lesions—in particular, atrophic gastri-
tis, intestinal metaplasia and dysplasia/intraepithelial neoplasia.
Various studies conﬁrm an increased gastric cancer risk in
patients with premalignant gastric lesions. For instance, a
nationwide study from the Netherlands including approximately
98 000 patients with premalignant gastric lesions reported, on
average, a 2–3% gastric cancer risk over 10 years.79 This risk
varied with the baseline stage of premalignant lesions, being
0.8%, 1.8%, 3.9% and 32.7% for patients with atrophic gastri-
tis, intestinal metaplasia, mild-to-moderate dysplasia and severe
dysplasia, respectively.79
These data conﬁrmed the association between presence of
premalignant gastric lesions and development of gastric cancer,
yet also showed that the risk for developing gastric cancer in an
individual with premalignant lesions is nevertheless small (2–6
per 1000 people per year). This necessitates the use of risk
stratiﬁcation methods.
Gastric biopsy sampling can be used to provide the most
important information for risk classiﬁcation. This led to the
OLGA staging system.16 17 This histological staging system
grades patients with gastritis into stages with corresponding
gastric cancer risk. Further studies showed that this staging
system provides relevant clinical information.80–82 Based on the
high prevalence of atrophic gastritis in at-risk populations and
the limited reproducibility and high interobserver variability in
histological diagnosis of atrophic gastritis, a further proposal
was made for the OLGIM system based on diagnosis and distri-
bution of intestinal metaplasia.18
The interobserver reproducibility was improved for intestinal
metaplasia compared with atrophic gastritis, and the correlation
between the severities of gastritis remained at least as strong.18
Subsequent studies with both the OLGA and OLGIM systems
showed a higher gastric cancer risk in patients in stage III or IV
of OLGA or OLGIM.82–84 As a result, upper gastrointestinal
surveillance endoscopy should be offered to patients in these
subcategories.
CQ15. Are serological tests (pepsinogen I, II, I/II, H. pylori
antibody) useful for risk stratiﬁcation?
Statement 15
Serological tests (pepsinogen I and II and H. pylori antibody)
are useful for identifying individuals at increased risk for gastric
cancer.
Grade of recommendation: strong
Evidence level: high
Consensus level: 91.9%
Comment
Serological tests for the diagnosis of chronic gastritis and gastric
atrophy have been in use for more than 25 years. These include
H. pylori serology (crude antigen with or without additional
determination of anti-CagA antibodies) for the diagnosis of gas-
tritis, and serum pepsinogen I and II and gastrin for the diagno-
sis of gland loss resulting in hypoacidity.85 These tests are
usually applied in panels of multiple tests and have been shown
to be a useful non-invasive diagnostic tool in an individual
patient, and as a population screening and surveillance tool.86 87
A Japanese cohort of 9293 screenees underwent serological
assessment by means of H. pylori serology and pepsinogen I
and II measurement.86 The annual progression to gastric cancer
was very low in subjects with normal pepsinogens, irrespective
of H. pylori status. The annual progression to gastric cancer was
substantially higher (3.5–6 per 1000 per year) in individuals
with low serum pepsinogen levels, compatible with presence of
atrophic gastritis.86 In the latter group, the incidence of gastric
cancer was higher among those with negative H. pylori serology
than among those with positive H. pylori serology, which is
indicative of progressive and widespread atrophy and metaplasia
impairing further H. pylori colonisation. Similar ﬁndings were
obtained in other studies.88 89
CQ16. When is it appropriate to search and screen for
H. pylori gastritis?
Statement 16
Depending on the epidemiological context, it is appropriate to
search and screen for H. pylori gastritis at an age before devel-
opment of atrophic gastritis and intestinal metaplasia.
Grade of recommendation: strong
Evidence level: moderate
Consensus level: 97.3%
Comment
H. pylori infection is mainly acquired in childhood, up to the age
of 12 years, in developed countries mostly by intrafamilial trans-
mission.90–92 The bacterium and associated gastritis persist life-
long, unless treated by eradication therapy, or unless end-stage
widespread atrophic gastritis and intestinal metaplasia occur. The
risk for gastric cancer depends on the grade of gastric atrophy
and intestinal metaplasia.31 82–84 86 H. pylori eradication can
reduce the risk for cancer, but this effect is largely conﬁned to
patients without atrophy and metaplasia.93–95 In patients with
these lesions, H. pylori eradication reduces gastritis, but may not
stop further progression to cancer. As a result, cancer can occur
more than 10 years after H. pylori eradication treatment.96
Against this background, it is appropriate to search and screen
for H. pylori gastritis at an age when new infections become less
likely (>12 years) and before development of atrophic gastritis
and intestinal metaplasia. This all depends on the geographical
location and epidemiological context, taking into account the
prevalence of infection and age-related cancer incidence.97
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Section 4 Management of gastritis
CQ17. Should all H. pylori-positive individuals receive eradica-
tion therapy?
Statement 17
H. pylori infected individuals should be offered eradication
therapy, unless there are competing considerations.
Grade of recommendation strong
Evidence level: high
Consensus level: 100%
Comment
H. pylori is a major human pathogen that causes chronic and
progressive gastric mucosal damage and is aetiologically related
to peptic ulcer, gastric cancer and gastric atrophy. It is also
closely associated with gastric MALT lymphoma, dyspepsia,
hyperplastic gastric polyps and idiopathic thrombocytopenic
purpura.5 12 46 47 61 98–104 H. pylori-positive individuals are
also the major reservoir for transmission of the infection.
The decision to eradicate a chronic infection in a society
should be based on quantitative data regarding the outcome of
untreated infections. H. pylori causes a chronic infection,
similar, for example, to asymptomatic syphilis or tuberculosis,
and the ﬁnal outcome for any individual cannot be predicted.105
H. pylori infection differs from many other chronic infectious
diseases because it is always transmissible, thus putting others at
risk. Because the gastric damage is progressive, the lack of an
obvious clinical manifestation at diagnosis has no predictive
value for life-time risk to an individual patient, their family or
to the community. Beneﬁts of H. pylori eradication for an indi-
vidual depend in part on the degree and extent of damage that
has already occurred and the reversibility of that damage.
Potential beneﬁts of eradication include stopping the progres-
sion of mucosal damage, stabilisation or reduction in risk of
developing gastric cancer, resolution of mucosal inﬂammation,
stabilisation or improvement of gastric mucosal function, return
of the normal mechanisms governing acid secretion, cure of
H. pylori-related PUD, reduction in risk of gastrointestinal com-
plications of NSAID therapy and prevention of future develop-
ment of H. pylori-related peptic ulcer.2 5 11 28 46 47 106–115
For society, the beneﬁts include reduction of the reservoir of
infected individuals capable of transmitting the infection to others,
and avoidance of the costs associated with diagnosis, management
and outcomes of H. pylori-related diseases that are prevented.
Thus, H. pylori-infected patients should be offered eradication
therapy unless there are competing considerations such as
comorbidities, re-infection rates in their communities, competing
health priorities of society and ﬁnancial cost. It has to be remem-
bered, however, that there are concerns about the negative impact
of eradication therapies on human health, such as increase in
allergy or obesity and perturbation of microbiota.116 117
CQ18. What is the optimal timing for H. pylori eradication in
asymptomatic subjects?
Statement 18
The maximum beneﬁt of H. pylori eradication is obtained if it is
done while the mucosal damage is still non-atrophic.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
H. pylori eradication always confers a beneﬁt by halting progres-
sion of gastric mucosal damage, reducing the reservoir of
infected individuals and reducing or preventing
H. pylori-associated diseases. The maximum beneﬁt of eradica-
tion for an individual is obtained if eradication is done while
the H. pylori-induced mucosal damage has not progressed
beyond the non-atrophic stage. This population is found in
countries where gastric cancer is still prevalent and is concen-
trated in the younger generation. H. pylori eradication of ado-
lescents and young adults has an additional advantage of
reducing or preventing transmission of the infection to their
children.
As noted above (Section 3), the risk for development of
gastric cancer correlates with the extent and severity of atrophic
gastritis. It is impossible to deﬁne the risk for an individual
based on age. Cancer risk in any population relates to the rate
of progression of gastric mucosal damage, which is high in
populations at high risk of cancer and low in H. pylori-infected
populations with a low cancer risk. Thus, while it is possible to
identify an average age at which the transition from non-
atrophic to atrophic phenotype occurs for any population, one
should expect that any age group will contain individuals with a
wide range of damage, ranging from uninfected (normal) to
advanced atrophy. This emphasises the need for risk stratiﬁca-
tion based on objective parameters including a validated histo-
logical staging system rather than on age, to identify whether
one eradication treatment is needed or whether the patient
might require surveillance.
The incidence of gastric cancer increases with age, which is a
surrogate marker for the time required for progression of atro-
phic gastritis. When atrophic gastritis becomes extensive and
severe, the risk increases exponentially. Cancer is the culmin-
ation of a multistep process of genetic instability, with cancer
cells possessing mutations in coding regions, somatic gene rear-
rangements and epigenetic changes such as methylation.
Current data are consistent with the notion that H. pylori eradi-
cation halts the progression of damage and reduces or eliminates
the H. pylori-associated events that increase genetic instability in
the gastric mucosa. These include infection-associated DNA
double-strand breaks,118 impaired DNA mismatch repair,119
aberrant activation-induced cytidine deaminase expression,
which induces nucleotide alterations involved in DNA muta-
tions,120 aberrant methylation in a number of gene promoters
in the gastric mucosa, including cell growth-related genes,
DNA-repair genes, tumour-suppressor genes, the cell adherence
gene E-cadherin and CpG islands of microRNA genes121–123
and aberrant microRNA expression.124 H. pylori infection also
causes an inﬂammatory response with mucosal inﬁltration of
acute and chronic inﬂammatory cells. Cancer risk is increased in
relation to the ability of the infecting strain to cause inﬂamma-
tion (eg, those possessing the Cag pathogenicity island).
However, all strains cause inﬂammation, and gastric cancer is
associated with infections lacking putative virulence factors.
Thus all H. pylori infections should be considered pathogenic
and should be eradicated.
Because of the damage and premalignant changes, H. pylori
eradication cannot ‘reset the clock’ to zero (ie, no risk) but can stop
the progression of risk and stabilise or decrease the subsequent risk.
CQ19. Do we need to adopt eradication regimens according to
the geographical area?
Statement 19
Eradication regimens should be based on the best locally effect-
ive regimen, ideally using individual susceptibility testing or
community antibiotic susceptibility, or antibiotic consumption
data and clinical outcome data. The agents available differ in
1362 Sugano K, et al. Gut 2015;64:1353–1367. doi:10.1136/gutjnl-2015-309252
Guidelines
different regions and this, in part, dictates what regimens are
possible.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
The success of a proven successful H. pylori eradication regimen
depends on the pattern of resistance in the population and on
the common host genotypes of drug metabolising enzymes in
the population. The prevalence of H. pylori resistance to com-
monly used antimicrobial agents greatly varies geographically
and is linked to consumption of antibiotics in the region,125 so
the preferred eradication regimen often differs between regions.
Ideally, treatment regimens should be chosen based on suscepti-
bility testing. Within any region, only regimens that reliably
produce eradication rates of ≥90% in that population should be
used for empirical treatment.5 126–129
CQ20. Does eradication of H. pylori prevent gastric cancer?
Statement 20
Eradication of H. pylori reduces the risk of gastric cancer. The
degree of risk reduction depends on the presence, severity and
extent of atrophic damage at the time of eradication.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
H. pylori infection is the most important cause of gastric cancer
as it is estimated that 89% of non-cardia gastric cancer, repre-
senting 78% of all cases of gastric cancer, can be attributed to
chronic H. pylori infection.130 Prevention of H. pylori infections
removes the primary cause of gastric cancer and will thus
reduce the incidence of gastric cancer in that population. The
effectiveness of H. pylori eradication for prevention of gastric
cancer depends on the severity and extent of atrophic damage
at the time of eradication and ranges from essentially complete
prevention for those with non-atrophic gastritis to stabilisation
or reduction of risk in those with established atrophic
changes.94 95 As noted in Section 3, risk can be stratiﬁed using a
variety of approaches, such as one of the validated histological
stratiﬁcation systems (eg, OLGA or OLGIM),16–18 and H. pylori
eradication can stabilise risk and halt the progression of
risk.28 94 Prevention of acquisition of H. pylori infections and
eradication of the infection before the development of atrophic
changes are forms of primary prevention. Secondary prevention
involves identiﬁcation and surveillance of those at risk in order
to remove intraepithelial lesions and early gastric cancer(s)
before they become invasive.5 71 72 77 131 There may be also a
role for cancer immunotherapy to treat premalignant lesions
and halt their progression to more advanced lesions.132
CQ21. Should the outcome of eradication therapy always be
assessed (ie, test for cure)?
Statement 21
The outcome of eradication therapy should always be assessed,
preferably non-invasively.
Grade of recommendation: strong
Evidence level: high
Consensus level: 100%
Comment
Failure of eradication is common and allows the mucosal damage
to progress, and so eradication should always be conﬁrmed,
preferably using a non-invasive test such as a urea breath test or a
validated monoclonal-based stool antigen test.5 For patients
requiring endoscopic follow-up, such as after endoscopic
removal of a gastric adenoma, histological assessment can be
used. Conﬁrmation of cure also provides an early warning system
for the increasing antibiotic resistance in a population that will
manifest as increasing rates of treatment failure.125 128 129
CQ22. Which patients need long-term follow-up after eradication?
Statement 22
H. pylori eradication may not completely eliminate the risk of
gastric cancer. Patients who remain at risk, as deﬁned by the
extent and severity of atrophy, should be offered endoscopic
and histological surveillance.
Grade of recommendation: strong
Evidence level: high
Consensus level: 97.3%
Comment
Long-term follow-up such as regular endoscopic surveillance
should be based on estimating the risk of developing gastric cancer
after H. pylori eradication (ie, risk stratiﬁcation).95 133 Cancer risk
correlates with the extent and severity of atrophic gastritis and risk
stratiﬁcation should be conﬁrmed using a validated histological
risk scoring systems such as OLGA or OLGIM.16–18 In areas with
proven expertise in endoscopic scoring, a system such as that of
Kimura and Takemoto can be used initially, although histological
conﬁrmation is still recommended.134 135 Patients whose H. pylori
infection was diagnosed non-invasively (eg, urea breath test or
stool antigen) should be considered for histological assessment.
These patients should include those within the age range in which
atrophic changes are common in that population and those with a
history of gastric ulcer as well as those with a pretreatment serum
pepsinogen I of ≤70 ng/mL and a pepsinogen I:II ratio ≤3.136–138
All those at especially high risk, including those at risk for intrae-
pithelial neoplasia (dysplasia) or early gastric cancer, are candidates
for regular endoscopic surveillance.
DISCUSSION
The global consensus meeting on H. pylori gastritis has set a
new landmark for gastritis, which has continued to be an ill-
conceived clinical entity placed between a histological picture
and upper abdominal symptoms.
In spite of the fact that gastritis had been long recognised as
an important clinical entity, generations of gastroenterologists
have neglected the importance of treatment of this nosological
entity. Rudolf Schindler described chronic gastritis as a serious
disease and a precursor of gastric cancer and considered their
relationship as being of outstanding importance in the ﬁght
against gastric cancer.139
The discovery of H. pylori has revolutionised the pre-existing
concepts of gastritis by assigning a speciﬁc aetiology to this
entity underlying PUD and gastric cancer. The majority of these
serious conditions are manifestations developed on the back-
ground of chronic gastritis caused by a unique infectious agent,
H. pylori. For PUD, guidelines unanimously recommend eradi-
cation as the primary treatment for those with positive H. pylori
tests. However, there has been no consensus on how and when
to manage individuals with H. pylori gastritis itself, which is
crucial to the efﬁciency of gastric cancer prevention because
most patients with chronic gastritis may remain asymptomatic
until the appearance of severe complications. Furthermore, both
gastritis and duodenitis were recognised as important causes of
upper gastrointestinal bleeding,140 encouraging our attention to
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these conditions now that anti-thrombotic therapies are increas-
ingly being used.
To further compromise the concept of gastritis as a signiﬁcant
clinical entity, the term ‘gastritis’ has historically, but wrongly,
been used as a substitute for a clinical diagnosis of FD.
Historical studies, however, failed to demonstrate a signiﬁcant
association between histological ﬁndings of gastritis and the dys-
peptic symptom complex.141 142 Hence, a potential pathogen-
etic role for H. pylori in causing dyspeptic symptoms was
initially considered doubtful and its eradication in FD controver-
sial.143 144 Meta-analysis of a large number of controlled trials
with longer follow-up conﬁrmed that eradication of H. pylori in
patients with FD conveys a small but statistically signiﬁcant
beneﬁt.12 Consequently, dyspepsia attributable to H. pylori gas-
tritis involves an underlying organic cause and should be
excluded from the FD category. Additionally, ‘dyspeptic’ patients
should not automatically be labelled as having ‘gastritis’ without
any histological conﬁrmation.
Diagnostic assessment of gastritis has been advanced by the
recent introduction of high-resolution endoscopy with image-
enhanced modalities, and magniﬁcation is now used routinely in
major hospitals in Japan. This endoscopic technology allows the
identiﬁcation of mucosal changes (for targeted biopsies) more pre-
cisely, leading to more accurate evaluation of cancer risks such as
preneoplastic changes. Wider use of this new endoscopic system
outside Japan may be limited at present.
The Kyoto consensus meeting focused attention on gastritis in
all its clinical expression and dealt with four main topics: classi-
ﬁcation of gastritis in relation to ongoing ICD revision, FD and
H. pylori infection, diagnosis of gastritis and the management
of gastritis. The methodology of the meeting adopted all
modern means for reaching consensus and included an internet-
based Delphi method with full access to published data in a
completely ‘neutral’ environment.
In summary, The Kyoto meeting proposed an aetiology-based
classiﬁcation for gastritis and concluded that H. pylori gastritis
is an infectious disease. As such, H. pylori gastritis requires treat-
ment whether or not it is associated with symptoms because it
represents a condition that may evolve towards serious compli-
cations, including peptic ulcer and gastric neoplasia.
Consensus was reached on the existence of a separate cat-
egory of patients with dyspeptic symptoms that are due to
H. pylori gastritis. In these patients, eradication therapy is the
recommended ﬁrst-line treatment. Because of the diagnostic
problems related to ‘gastritis’, these patients should be labelled
as having H. pylori-associated dyspepsia and are identiﬁed by
sustained dyspeptic symptom relief after eradication.
For the diagnosis of gastritis, it was agreed that risk stratiﬁca-
tion systems such as OLGA and OLGIM are useful as are the
serological markers. In view of recent technological advance-
ments, image-enhanced endoscopy should be encouraged for
identifying mucosal changes which carry a high risk of develop-
ing into gastric neoplasia. Finally, it was recommended that
early eradication therapy, ideally before preneoplastic changes
occur, should be undertaken. However, the feasibility of imple-
menting this strategy should be regionally tailored. As eradica-
tion therapy does not guarantee elimination of the risk of
gastric cancer, follow-up should be considered for patients who
have preneoplastic conditions.
Although there are still many remaining areas to be discussed,
we believe the outcome of the Kyoto consensus meeting pre-
sented in this report will improve patient care and will provide
a cornerstone for further reﬁnement and research in the area of
gastritis.
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